DOCSLIB.ORG

Drug “Allergy” Is No Allergy a View Back, with Some Surprising Conclusions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug “Allergy” Is No Allergy a View Back, with Some Surprising Conclusions Drug “allergy” is no allergy a view back, with some surprising conclusions Werner J. Pichler, MD [email protected] [email protected] Division Allergology, Inselspital, ADR-AC GmbH University of Bern, Adverse Drug Reactions – CH 3010 Bern Analysis and Consulting Switzerland Holligenstr 91, CH 3008 Bern, Switzerland Drug allergy allergy an immune response to an innocous substance which leads to symptoms an immune response to a drug or drug- drug allergy metabolite which leads to clinical symptoms activation of innate and adaptive immunity, immune response stimulation of specific T-cells and specific antibodies, inflammatory reaction drug often < 1000 D; small molecules are per se not immunogenic, covalent binding to carrier protein (hapten-carrier complex) required for «immunogenicity» Adverse Drug Reaction (type B): Drug Allergy • anaphylaxis, urticaria • maculo-papular exanthema • bullous exanthema • acute generalized exanthematous pustulosis (AGEP) • Stevens-Johnson Syndrome (SJS) toxic-epidermal necrolysis (TEN) • DRESS, hepatitis , interstitial nephritis,pneumonitis • drug induced autoimmunity (SLE, pemphigus, ...) BIZARRE CLINIC PURPOSE OF IMMUNE REACTION ? How are drugs stimulating the immune system ? Hapten/prohapten specific immunity Penicillin G SMX-NO Haptens are chemically reactive R N H O compounds able to bind H H C N CH S O S 3 H2 covalently to proteins. CH N 3 I O ON a Adduct formation gives a danger N O N N O signal to APC (CD86 A upregulation, IL-1b-secretion) T E Adduct formation forms A neoantigenic determinants able D to induce both a T-cell and B-cell A P immune response. A hapten T stimulates both, T- cells and B- I processing cells !! V E Adverse drug reactions: Drug allergy is a type B reaction Type A reaction Type B reaction Pharmacological action 1 Not a pharmacological action Predictable 2 Not predictable Dose dependent 3 Not dose dependent Rational 4 Not explainable, bizarre MD Rawlins, JW Thompson: IR Edwards, JK Aronson: Pathogenesis of adverse drug reactions; Adverse drug reactions: definitions, Textbook of adverse drug reactions, diagnosis, and management Oxford (1977 & 1981), LANCET (2000) 356: 9237; 1255-1259 DM Davies (Ed.), Oxford Univ. Press, p. 10 & p11 Adverse drug reactions Type A reaction Type B reaction Pharmacological action 1 Not pharmacological action Predictable 2 Not predictable Dose dependent 3 Not dose dependent Rational 4 Not explainable, bizarre The consequence of this «not» classification (type B) are: 1. ADR Type B were considered to be due to the patient: «idiosyncrasy»: the drug is OK, the patient is weird 2. Type B reactions cannot be analysed in usual risk assessments: «fatalism» 3. Dose reduction not considered in avoidance of type B 4. The clinical picture was not explainable, it is «bizarre» Type B reaction as an excuse to do nothing ?? Adverse drug reactions Type A reaction Type B reaction Pharmacological action 1 Not pharmacological action Predictable 2 Not predictable AlainDose de Weck:dependent don`t build your scientific3 Not dose career dependent on research about drug hypersensitivity ! Rational 4 Not explainable, bizarre It isT ahe neglected consequence field of, not this very «not» popular classification with money (type givers B) are (grants: ) no 1.animalADR models Type B, weremainly considered case records to be, seldom due to systematic the patient : investigations«idiosyncrasy, since »:the the topic drug is bizarreis OK, the – your patient research is weird may be considered2. Type bizarreB reactions ........ cannot be analysed in usual risk assessments: «fatalism» 3. Dose reduction not considered in avoidance of type B 4. The clinical picture was not explainable, it is «bizarre» Adverse drug reactions “As more becomes known about the mechanisms of Drug allergy specific adverse drug effects, 1 Not pharmacological action this classification will be revised 2 Not predictable further and classification of currently unclassifiable 3 Not dose dependent ? reactions will become easier” 4 Not explainable, bizarre Edwards & Aronson: LANCET, 356: 1255, 2000 1984 Drug allergy: maculopapular drug eruption(MPE) 45 40 35 30 25 20 15 10 5 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Lymphocyte Transformation Test In PBMC: Stimulation 3H-Thymidine vitro by drug, Incorporation expansion cytotoxicity In vitro PBMC: Stimulation 3H-Thymidine by drug, Incorporation expansion cytotoxicity Lymphocyte transformation test (LTT): To stimulate T cells in vitro with drugs and to conclude to a drug allergy..... ?? Delirant isti helvetii LTT: stimulation of PBMC by drugs 1986 Konz. Autol. Plasma AB-Serum Medikament/Substanz microg SI SI Phenytoin RS 1 16.2 18.7 10 55.1 81.7 50 93.3 72.9 100 63.5 63.8 Lamotrigin RS 0.1 1.4 1.5 1 1.6 1.9 10 2.6 4.4 100 2.9 19.6 Pantoprazol RS 0.1 1.2 1.1 1 2.0 1.0 10 1.1 1.8 50 0.2 0.3 Positive LTT for phenytoin and lamotrigine (DRESS) dose dependent, reaction in PBMC, no liver (metabolism) LTT: stimulation of PBMC by drugs 1986 Konz. Autol. Plasma AB-Serum Medikament/Substanz microg SI SI Phenytoin RS 1 16.2 18.7 10 55.1 81.7 50 93.3 72.9 100 63.5 63.8 LamotriginA RS clear result should0.1 be repeated1.4 , and1.5, 1 1.6 1.9 if confirmed, should10 not and2.6 can not 4.4 be ignored100 2.9 19.6 Pantoprazol RS 0.1 1.2 1.1 Delirant isti1 helvetii2.0 1.0 10 1.1 1.8 50 0.2 0.3 Positive LTT for phenytoin and lamotrigine (DRESS) dose dependent, reaction in PBMC, no liver (metabolism) 1992-1999 Tony Wyss-Coray Christian Brander Daniela Mauri-Hellweg Benno Schnyder Karin Frutig-Schnyder Martin Zanni Salomé von Greyerz Drug specific T-cell clones (TCC) Immunohisto- from blood and tissue chemistry cell culture with drug Expansion of a single cell T-cells Nikhil Yawalkar T-cells TCC phenotype function: cytokines, cytotoxicity proliferation interaction with APCs, tissue cells Perforin - CD4 drug recognition cross-reactivity red - brown Drug stimulated T cells are peculiar 2002 HLA-DR-allele Binding from the independent drug outside to the MHC- APC peptide complex recognition peptide MHC-molecule Additional specificity: MHC class II CD3-TCR drug complex restricted CD8+ high incidence of T cells alloreactivity T cell CD4 and CD8 Oligoclonal TCR Vb T cells stimulated expansion T cell activation How are drugs stimulating T cells ? starts within seconds of drug exposure. Immediate Ca++ influx to oxypurinol (OXP) Hapten Proteasome is formation is not required. not required. The best control for your experiments is questioning it by a new PhD student (or by Dean Naisbitt): he/she will not believe what has been done previously. But when she/he is convinced, your data are solid ! 2000 - 2006 Christoph Burkhardt Dean Naisbitt Nikhil Yawalkar Jan Depta Markus Britschgi Urs Steiner Andreas Beeler Yvonne Hari Oliver Engler Petra Kuechler Antigenicity of a drug DOGMA: “a small compound (<1000D) is not a complete antigen” It is necessary that a drug binds covalently (as a “hapten”) to a carrier molecule to be able to stimulate the immune system ? or can a drug directly stimulate certain immune cells as well, without covalently binding to a carrier molecule ? (p-i-concept) Alain de Weck: be progressive in research but conservative in clinic 2002- 2004 «Pharmacological interaction with immune receptors» = p-i concept 1. Non-covalent binding of drugs to proteins functioning as immune receptors (TCR, HLA) 2 p-i explains an immune stimulation by a drug without postulating antigen-features of a drug ! 3 Landsteiner et al. were right: small molecules do not act as antigen, but they have other means of stimulating the immune system TCR progress means also to change dogma: drugs can stimulate T cells without covalent binding (hapten characteristics) pharmacological interaction with immune receptors p-i concept (2002) ? the drug binds to HLA immune receptor proteins (HLA or TCR)?? (by non-covalent bonds, independent on processing, metabolism, immediately) HLA-peptide-TCR complex Adverse drug reactions Type B reaction Type A reaction immune mediated Pharmacological action 1 Not pharmacological action Predictable 2 Not predictable Dose dependent 3 Not dose dependent Rational 4 Bizarre (immune-mediated = complex diseases !!) Some immune mediated reactions to drugs are «off target» (pharmacological) activities of the drug on immune receptors. TCR transfectionsT11.1 ) -3 10 NRFX (20 g/ml) 2006-2010 8 6 4 2 0 H-thymidine incorporation (cpm x 10 x (cpm incorporation H-thymidine Monika Keller 3 0 250 500 1000 2500 5000 6250 10000 1250025000 50000 105 2.105 4.105 APC (cells/well) Zoi Spanou Interstitial nephritis Cytotoxic mechanism Marianne Lerch Simone Schmid Daphne Schmid Basil Gerber Anna Zawodniak IL-5 IFN-g Precursor Priska Lochmatter analysis phenytoin phenytoin Progress from an unexpected site far away: A U S T R A L I A Lancet 2002: 359:727-737 T A marker for Stevens-Johnson Syndrome A Wen-Hung Chung*, Shuen-Iu Hung†, Hong-Shang Hong*, I Mo-Song Hsih‡, Li-Cheng Yang*, Hsin-Chun Ho*, Jer-Yuarn Wu†§, W Yuan-Tsong Chen†¶ Departments of *Dermatology and ‡Neurology, A Chang Gung Memorial Hospital, Taipei, Taiwan †Institute of Biomedical Sciences, N Academia Sinica, Taipei, Taiwan NATURE|VOL 428 | 1 APRIL 2004 |www.nature.com/nature p-i concept (p-i HLA) TCR a drug fits into a particular HLA molecule the drug binds to an allele-typic region in the HLA by van der Waals forces; it does not bind to the peptide; the {HLA-peptide-drug} complex is then recognized by the TCR HLA-B*5701: binding groove HLA for abacavir Illing et al, Nature 2012 HLA-peptide-TCR complex Ostrov D et al, PNAS 2012 HLA polymorphism in population ca 14 HLA alleles / individual ca.
Load more

Recommended publications
  • Xii World Asthma, Allergy & Copd Forum
    XII WORLD ASTHMA, ALLERGY & COPD FORUM Saint Petersburg, Russia June 29–July 2, 2019 SAINT PETERSBURG SAINT PROGRAM World Immunopathology XIII WORLD ASTHMA, Organization (WIPO) ALLERGY & COPD FORUM Saint-Petersburg, Russia July 2–5, 2020 General Information St. Pet The World Immunopathology Organization (WIPO) is a professional, non-profit organization. WIPO was created in December 2002, at the I World Congress on Immunopathology in Singapore. During these years, WIPO successfully organized many international congresses and regional and national meetings throughout See you in Saint Petersburg in 2020! the world all promoting basic and clinical research and giving an opportunity for exchanging ideas. WIPO is aimed at collecting and disseminating scientific information and providing training and continuous education in various fields of immunopathology. Aims and Mission Nowadays, immunopathology has become a multidisciplinary problem. The WIPO global mission is to promote through education and research activities worldwide: – basic and clinical research in experimental and clinical immunology, allergy and asthma, autoimmunity, immunodeficiency, AIDS, immunobiotechnology, – prevention and treatment of different manifestations of immunopathology—immune-associated disorders, – excellence in patient care in this very important area of medicine and to establish communication between specialists in various fields of medical science and practice. e We encourage to join WIPO national and regional societies as well as individual members—doctors
    [Show full text]
  • ÖGAI Symposium 2015 50 Years of B-Lymphocytes
    ÖGAI Symposium 2015 50 Years of B-Lymphocytes Delineation of the Thymic and Bursal Lymphoid Systems in the Chicken. Cooper, MD, Peterson RD, Good RA Pediatric Res.Lab. of the Variety Club Heart Hospital, Univ. of Minnesota, Minn., USA Nature, 1965, 205:143-6 December 11-12, 2015 College of Physicians in Vienna, Billrothhaus 1090 Vienna, Frankgasse 8 PROGRAMME ABSTRACTS Welcome Dear guests, dear colleagues and friends, We cordially welcome you to the symposium ‘50 Years of B-Lymphocytes’ which is organized by the Austrian Society for Allergology and Immunology, ÖGAI, in Vienna, from December 11-12, 2015. With this symposium we are celebrating the discovery of B-lymphocytes, which play a key role in the defense against pathogens, tumors, and environmental factors potentially harming human beings. The understanding of B lymphocytes and antibodies produced by these cells is also crucial for the understanding of the large variety of diseases such as allergies, autoimmune diseases, immunodeficiencies and other immune-mediated diseases. The symposium will take place in the historical building of the College of Physicians in Vienna, the Billroth-Haus. The program consists of plenary lectures, given by outstanding international scientists, selected oral presentations by members of the Austrian Society for Allergology and Immunology, ÖGAI, and five poster sessions, which offer early career scientists to present their cutting edge research. On the occasion of this meeting the Austrian Society for Allergology and Immunology is proud to award the Clemens von Pirquet medal to Prof. Gabriel Pauli from Strasbourg, France, and the Karl Landsteiner Medal to Prof. Lorenzo Moretta from Rome, Italy.
    [Show full text]
  • In Memoriam Professor De Weck
    Letters to the Editor In Memoriam Professor De Weck The speciality of allergology recently suffered the loss of Professor Alain de Weck. For almost 30 years, Professor de Weck was the Director of the Institute of Clinical Immunology and Allergy at the University of Bern, Switzerland, where he started his research in immunopathology and the dynamics of hypersensitivity in drug allergy (penicillin), before moving on to study the immunological mechanisms of allergic reactions at the cellular level. His work was reÁ ected in major studies that generated more than 500 articles, as well as in several books and publications. The research led by Professor de Weck played a key role in promoting allergology throughout the world. Professor de Weck was also an energetic promoter of allergology as an academic discipline. retirement in 1993 and until 4 years ago, he devoted himself Professor de Weck devoted part of his time to international to research, together with my colleague Professor Sanz, with societies such as the International Union of Immunology whom he published more than 20 articles. His role as Associate Societies (IUIS) and the International Association of Editor at the Journal of Investigational Allergology and Clinical Allergology and Clinical Immunology (IAACI), both of Immunology was an enormous help to me. which he served as President. It was in the IAACI, of which Finally, I would like to highlight his generous and positive I was also President, where we began a friendship that lasted idea of combining his library of allergology and clinical almost 20 years. He was also a key member and president of immunology with mine to create a legacy that is now available the Collegium Internationale Allergologicum (CIA), which in the Library of the School of Medicine of the University of beneÀ ted greatly from his efforts.
    [Show full text]
  • Immunology of the Allergic Response 1
    9781405157209_4_001.qxd 4/1/08 20:03 Page 1 1 Immunology of the Allergic Response 9781405157209_4_001.qxd 4/1/08 20:03 Page 2 .. 9781405157209_4_001.qxd 4/1/08 20:03 Page 3 1 Allergy and Hypersensitivity: History and Concepts A. Barry Kay Summary The study of allergy (“allergology”) and hypersensitivity, and the associated allergic diseases, have their roots in the science of immunology but overlap with many disciplines including pharmacology, biochemistry, cell and molecular biology, and general pathology, particularly the study of inflammation. Allergic diseases involve many organs and tissues such as the upper and lower airways, the skin, and the gastrointestinal tract and therefore the history of relevant discoveries in the field are long and complex. This chapter gives only a brief account of the major milestones in the history of allergy and the concepts which have arisen from them. It deals mainly with discoveries in Fig. 1.1 A commemorative postage stamp to mark the discovery the 19th and early 20th century, particularly the events which of anaphylaxis by Charles R. Richet (1850–1935) and Paul J. Portier followed the description of anaphylaxis and culminated in the (1866–1962). discovery of IgE as the carrier of reaginic activity. An important conceptual landmark that coincided with the considerable foreign proteins to various species including dogs (Magendie increase in knowledge of immunologic aspects of hypersensitivity 1839), guinea pigs (Von Behring 1893, quoted in Becker 1999, was the Coombs and Gell classification of hypersensitivity p. 876) and rabbits (Flexner 1894, reviewed in Bulloch 1937). reactions in the 1960s. This classification is revisited and updated However it was not until the discovery of anaphylaxis by to take into account some newer finding on the initiation of the allergic response.
    [Show full text]
  • Development of Certified Reference Materials for Allergenic Products
    Allergy 2008: 63: 310–326 Ó 2008 The Authors Journal compilation Ó 2008 Blackwell Munksgaard DOI: 10.1111/j.1398-9995.2007.01612.x EU Forum The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification Allergen extracts have been used for diagnosis and treatment of allergy for R. van Ree1, M. D. Chapman2*, F. around 100 years. During the second half of 20th century, the notion increas- Ferreira3*, S. Vieths4*, D. Bryan5*, ingly gained foothold that accurate standardization of such extracts is of great O. Cromwell6*, M. Villalba7*, importance for improvement of their quality. As a consequence, manufacturers S. R. Durham8*, W. M. Becker9*, have implemented extensive protocols for standardization and quality control. M. Aalbers10,C.AndrØ11, D. Barber12, These protocols have overall IgE-binding potencies as their focus. Unfor- A. Cistero Bahima13, A. Custovic14, tunately, each company is using their own in-house reference materials and their A. Didierlaurent11, C. Dolman5, own unique units to express potencies. This does not facilitate comparison of J. W. Dorpema15, G. Di Felice16, different products. During the last decades, most major allergens of relevant F. Eberhardt9, E. Fernandez Caldas17, allergen sources have been identified and it has been established that effective M. Fernandez Rivas18, H. Fiebig6,M. immunotherapy requires certain minimum quantities of these allergens to be Focke19, K. Fçtisch4, G. Gadermaier3, present in the administered maintenance dose. Therefore, the idea developed to R. G. Das5, E. Gonzalez Mancebo20, introduce major allergens measurements into standardization protocols. Such M. Himly3, T. Kinaciyan19, protocols based on mass units of major allergen, quantify the active ingredients 21 22 9 of the treatment and will at the same time allow comparison of competitor A.
    [Show full text]
  • Xi World Asthma, Allergy & Copd Forum
    XI WORLD ASTHMA, ALLERGY & COPD FORUM Barcelona, Spain April 20–23, 2018 GENERAL INFORMATION CONGRESS VENUE The Renaissance Barcelona Fira Hotel is the Headquarters of the XI World Asthma, Allergy & COPD Forum. DATES LANGUAGE April 20–23, 2018 The official language of the Congress is English. REGISTRATION The registration desk will open in the Renaissance Barcelona Fira Hotel: April 20, 14.00 – 19.00 in the Lobby of the Hotel April 21, 09.00 – 16.00 in the Foyer of the Main Congress Hall (Europa 2+3) April 22, 10.00 – 16.00 in the Foyer of the Main Congress Hall (Europa 2+3) April 23, 10.00 – 14.00 in the Foyer of the Main Congress Hall (Europa 2+3) NAME BADGES All Congress participants, official guests, accompanying persons are kindly requested to wear their name badges for the participation in all scientific sessions and social events of the Congress. OPENING CEREMONY The Opening Ceremony of the XI World Asthma, Allergy & COPD Forum will be held in the Main Congress Hall (Europa 2+3), Renaissance Barcelona Fira Hotel on April 21, at 10.00 a.m. Admission by name badges. ORAL PRESENTATIONS Oral presentations last up to 20 min in plenary sessions and symposia. Keynote and memorial lectures last from 30 min to 45 min including question. PPT PRESENTATIONS AND SLIDES Power Point Presentations (on CD or flash) should be handed to the representative of the Congress Secretariat in advance but not later than 15 min prior to the start of the session. POSTER PRESENTATIONS All posters should be displayed in the poster area of the Main Congress Hall (Europa 2+3) according to the Congress Program on April 21 and 22.
    [Show full text]
  • Progress in Immunology Vol
    Progress in Immunology Vol. VII Proceedings of the 7th International Congress of Immunology Berlin 1989 Editors: F. Melchers E.D. Albert, H. von Boehmer, M.P. Dierich, L. Du Pasquier, K. Eichmann, D. Gemsa, O. Gotze, J.R. Kalden, S.H.E. Kaufmann, H. Kirchner, K. Resch, G. Riethmiiller, A. Schimpl, C. Sorg, M. Steinmetz, H. Wagner, H. G. Zachau Editorial Assistance: L. Nicklin With 255 Figures and 184 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong FRITZ MELCHERS Basel Institute for Immunology Grenzacherstrasse 487 4005 Basel, Switzerland Names and addresses of the other editors can be found on page LX ISBN-13 : 978-3-642-83757-9 e-ISBN-t3 : 978-3-642-83755-5 DOl : 10.1007 /978-3-642-83755-5 Library of Congress Catalog Card Number 19-640888 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its version of June 24,1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1989 Softcover reprint of the hardcover I st edition 1989 The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]
  • Performance Report 2014
    Performance Report 2014 Department of Pathophysiology & Allergy Research Center of Pathophysiology, Infectiology and Immunology Medical University Vienna Coordinated by: Marion Sack Content Page Introduction 3 Organigram 6 Personnel 9 Impulsseminare 11 1. Detailed Reports of Divisions 13 1.1. Division for Comparative Immunology and Oncology 13 1.2. Division for Cellular and Molecular Pathophysiology 39 1.3. Division for Immunopathology 65 1.4. Division for Medical Biotechnology 89 1.5. Division for Allergy Research 109 Rooms 119 Social Events 121 Science knows no country because it is the light that illuminates the world. Louis Pasteur __________________________________________________________________________ As head of the Institute of Pathophysiology and Allergy Research (IPA) I am proud to introduce this detailed overview on our scientific and academic achievements by mentioning that 2014 has been a successful year! I would like to continue this performance report by announcing that the budget situation has improve and that funding of research has increased, however, this is unfortunately not true. Nevertheless, despite the current situation of more and more restricted funding and a reduction of personnel the IPA has shown that it can rely on a very strong team. During the past year, we have continued to grow together, our team spirit has increased and the internal communication has improved. These developments led to a remarkable output in terms of science and academic teaching. I wish to express my sincere thanks to all IPA members who have contributed to our notable success! I also wish to express my sincere thanks to Univ. Prof. Hannes Stockinger, the head of the centre for Pathophysiology, Infection, and Immunology (CePII), for his continuous support and transparent policy.
    [Show full text]
  • Ix World Asthma, Allergy & Copd Forum X Cis Congress
    IX WORLD ASTHMA, ALLERGY & COPD FORUM Ƈ X CIS CONGRESS ON ALLERGOLOGY AND IMMUNOLOGY Saint Petersburg, Russia July 1–4, 2016 GENERAL INFORMATION CONGRESS VENUE TheWĂƌŬ/ŶŶWƌŝďĂůƚŝLJƐŬĂLJĂ,ŽƚĞů is the Headquarters of the IX World Asthma, Allergy & COPD Forum and the X CIS Congress on Allergology and Immunology. DATES July 1–4, 2016 LANGUAGE The official languages of the meeting are English and Russian. On July 2 and July 3, simultaneous translation will be available for the plenary lectures. REGISTRATION The registration desk will open in the WĂƌŬ/ŶŶWƌŝďĂůƚŝLJƐŬĂLJĂ,ŽƚĞů: July 1, 14.00 – 20.00 July 2, 09.00 – 16.00 July 3, 10.00 – 16.00 July 4, 10.00 – 14.00 NAME BADGES All Congress participants, official guests, accompanying persons are kindly requested to wear their name badges for the participation in all scientific sessions and social events of the Congress. Admission to World Allergy Training School (WATS) by invitations only. OPENING CEREMONY The Opening Ceremony of the IX World Asthma, Allergy & COPD Forum and the X CIS Congress on Allergology and Immunology will be held in the Main Congress Hall of the WĂƌŬ /ŶŶ WƌŝďĂůƚŝLJƐŬĂLJĂ ,ŽƚĞů, on July 1, at 10.00 a.m. Admission by name badges. ORAL PRESENTATIONS Oral presentations last up to 20 min in plenary sessions and symposia. Keynote and memorial lectures last up to 30 min including questions. PPT PRESENTATIONS AND SLIDES Power Point Presentations (on CD or flash) should be handed to the representative of the Congress Secretariat in advance but not later than 15 min prior to the start of the session.
    [Show full text]
  • Mallorca Final
    Allergy Across the Life Course - From Origins Towards Prevention 32nd Symposium of the Collegium Internationale Allergologium 30 SEPT - 5 OCT 2018 Mallorca SPAIN Final PROGRAM TABLE OF CONTENTS Welcome Letter........................................................................................... 1 General Information........................................................................................ 2 Social Events ............................................................................................ 2 Optional Excursions ........................................................................................ 3 Program-at-a-Glance........................................................................................ 4 Alain L. de Weck Travel Grant Recipients .......................................................................... 6 Schedule of Events ........................................................................................ 7 Abstracts .............................................................................................. 17 Speaker and Chair Index.................................................................................... 75 Supporters ....................................................................................... Back Cover 30 SEPTEMBER - 5 OCTOBER 2018 Mallorca SPAIN 32nd Symposium of the Collegium Internationale Allergologicum 2016-2018 Dear Friends, COLLEGIUM COUNCIL On behalf of the Council, Marianna Castells and I welcome you to the 32nd Symposium of the Collegium Internationale
    [Show full text]
  • Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives Than Pitfalls
    Opinion Article Int Arch Allergy Immunol 2008;146:177–189 Received: June 25, 2007 DOI: 10.1159/000115885 Accepted after revision: October 18, 2007 Published online: February 11, 2008 Diagnostic Tests Based on Human Basophils: More Potentials and Perspectives than Pitfalls a a b d e A.L. de Weck M.L. Sanz P.M. Gamboa W. Aberer J. Bienvenu c f h c e g M. Blanca P. Demoly D.G. Ebo L. Mayorga G. Monneret J. Sainte-Laudy a b c University of Navarra, Pamplona , Hopital Basurto, Bilbao , and Carlos Haya Hospital, Malaga , Spain; d e f g University of Graz, Graz , Austria; Centres Hospitaliers Universitaires, L y o n , Montpellier and L i m o g e s , F r a n c e ; h Department of Immunology, University of Antwerp, Antwerp , Belgium Key Words sons to deprive allergic patients of clinically indicated BAT, -Basophil activation ؒ Drug allergy ؒ Flow cytometry ؒ which can be performed reliably by any laboratory with al .Food allergy ؒ Insect venoms ؒ ␤ -Lactams ؒ Latex ؒ lergy and flow-cytometric capacity and expertise Myorelaxants ؒ NSAID Copyright © 2008 S. Karger AG, Basel Abstract Introduction For the diagnosis of allergy, cellular basophil activation tests (BAT), e.g. histamine or sulfidoleukotriene release tests, have In a recent issue of this Journal an opinion paper was long been introduced, but the expression of basophil acti- devoted to diagnostic tests in allergy based on human vation markers such as CD63 and CD203c detected by flow basophils [1] . Although reviewing first many publica- cytometry has attracted more recent attention.
    [Show full text]
  • Personal Reflections of a Board Member, Vice President, Congress
    NOTES OF ALLERGY WATCHERS History of the World Allergy Organization: Personal Reflections of a Board Member, Vice President, Congress Organizer, and Journal Editor Johannes Ring, PhD, MD Key Words: World Allergy Organization, World Allergy Organiza- Immunology (IAACI), has good reasons to be proud. The tion Journal, World Allergy Congress 2005, Allergy and Clinical history of this organization is somehow highlighting Immunology News the progress of the discipline in the second half of the 20th – century and the beginning of our millennium. My humble (WAO Journal 2011; 4:147 150) task is just to reflect on the years where I had the chance to participate in the development of this organization. History of the World Allergy Organization: In 1951, the leaders in allergy from all over the world came together to form the International Association of Aller- gology and Clinical Immunology (IAACI). For the next CONGRESSES 60 years, the allergy world converged at the IAACI triennial meetings, which became biennial in 2003. “International Congress of Allergology and The international meetings, originally named the Inter- Clinical Immunology”d“World national Congress of Allergology and Clinical Immu- Allergy Congress” nology (ICACI), are now the World Allergy Congress As a matter of fact, my first contact with IAACI was in (WAC) hosted by the World Allergy Organization 1973 when I wanted to attend the International Congress of (WAO). Everyone who has aspired to have worldwide Allergology and Clinical Immunology (ICACI) in Tokyo; in recognition has played a part in IAACI-WAO. The His- those days I, was working in experimental immunology tory of the World Allergy Organization traces the trying to prevent organ transplant rejection with horse anti- global arc of the allergy field over the past 60 years.
    [Show full text]